Abstract
In view of the significant cognitive deficits in schizophrenia and their impact on patients’ social and occupational functioning, and considering that the influence potential influence of antipsychotic-induced extrapyramidal symptoms on cognition in schizophrenia remains poorly understood, the current study sought to identify the clinical, socio-demographic and neurologic predictors of the cognitive performance of schizophrenia patients. Eighty-two schizophrenia-spectrum (DSM-IV criteria) outpatients were recruited. Psychiatric symptoms were evaluated with the Positive And Negative Syndrome Scale and the Calgary Depression Scale for Schizophrenia. Extrapyramidal symptoms were evaluated with the Extrapyramidal Symptoms Rating Scale, while spatial working, planning abilities and visual paired associates learning were evaluated with the CAmbridge Neuropsychological Tests Automated Battery. The Stroop test was also administered. Multivariate hierarchic linear regression analyses were performed. We found that negative symptoms were associated with cognitive flexibility, planning, visual learning and working memory performance in schizophrenia. Age, sex, number of hospitalizations and antipsychotic type also emerged as significant predictors. More importantly, we found a significant association between antipsychotic-induced parkinsonism and working memory performance. The fact that negative symptoms and socio-demographic variables predicted cognitive performance in schizophrenia is consistent with the previous literature on the topic. The finding of an association between parkinsonism and working memory may have clinical implications, since working memory deficits are considered putative endophenotypes of schizophrenia and are known to impair patients’ social and occupational functioning. Our results will need to be replicated in longitudinal studies involving larger samples of patients.
Similar content being viewed by others
References
Kalkstein S, Hurford I, Gur RC (2010) Neurocognition in schizophrenia. Curr Top Behav Neurosci 4:373–390
Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29–39
Stip E (2006) Cognition, schizophrenia and the effects of antipsychotics. Encephale 31:341–350
Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330
Ventura J, Helleman GS, Thames AD, Koellner V, Nuechterlein KH (2009) Symptoms as mediators of the relationship between neurocognition and functional outcomes in schizophrenia: a meta-analysis. Schizophr Res 113:189–199
Mendrek A, Stip E (2011) Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Exp Rev Neurother 11:951–959
Shah JN, Qureshi SU, Jawaid A, Schulz PE (2012) Is there evidence for late cognitive decline in chronic schizophrenia? Psychiatr Q 83:127–144
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatment meta-analysis. Lancet 382:951–962
Tandon R, Jibson MD (2002) Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 14:123–129
Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M (2001) Subjective response to antipsychotic treatment and compliance in schizophrenia: a naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 1:7
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844
Pagonabarraga J, Kulisevsky J (2012) Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis 46:590–596
Kudlicka A, Clare L, Hindle JV (2011) Executive functions in Parkinson’s disease: systematic review and meta-analysis. Mov Disord 26:2305–2315
Kim JH, Byun HJ (2009) Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol Clin Exp 24:129–133
Süllwold L (1977) Symptome schizophrener Erkrankungen: Uncharakteristische Basisstörungen. Springer, Berlin
Krausz M, Moritz SH, Naber D, Lambert M, Andresen B (1999) Neuroleptic-induced extrapyramidal symptoms accompanied by cognitive dysfunction in schizophrenia. Eur Psychiatry 14:84–88
Tanaka T, Tomotake M, Ueoka Y, Kaneda Y, Taniguchi K, Nakataki M, Numata S, Tayoshi S, Yamauchi K, Sumitani S, Ohmori T, Ueno SI, Ohmori T (2012) Clinical correlates associated with cognitive dysfunction in people with schizophrenia. Psychiatry Clin Neurosci 66:491–498
Palmer BW, Heaton RK, Jeste DV (1999) Extrapyramidal symptoms and neuropsychological deficits in schizophrenia. Biol Psychiatry 45:791–794
Pantelis C, Stuart GW, Nelson HE, Robbins TW, Barnes TRE (2001) Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry 158:1276–1285
Wu JQ, Chen DC, Xiu MH, Tan YL, Yang FD, Kosten TR, Zhang XY (2013) Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 46:71–77
Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RSE, Rosenheck RA, Stroup TS, Lieberman JA (2005) Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80:33–43
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201–208
Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76:247–265
Knol W, Keijsers CJ, Jansen PA, van Marum RJ (2010) Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol 30:57–63
Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1998) Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cogn Neuropsychiatry 3:45–70
Levaux MN, Potvin S, Sepehry AA, Sablier J, Mendrek A, Stip E (2007) Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry 22:104–115
Golden CJ (1978) Stroop color and word test: a manual for clinical and experimental uses. Stoelting, Wood Dale, IL
Rajji TK, Mulsant BH (2008) Nature and course of cognitive function in late-life schizophrenia. Schizophr Res 102:122–140
Jimenez JA, Mancini-Marie A, Lakis N, Rinaldi M, Mendrek A (2010) Disturbed sexual dimorphism of brain activation during mental rotation in schizophrenia. Schizophr Res 122:53–62
Torniainen M, Suvisaari J, Partonen T, Castaneda AE, Kuha A, Perala J, Saarni S, Lonnqvist J, Tuulio-Henriksson A (2011) Sex differences in cognition among persons with schizophrenia and healthy first-degree relatives. Psychiatry Res 188:7–12
Cuesta MJ, Sanchez-Torres Am, de Jalon EG, Campos MS, Ibanez B, Moreno-Izco L, Peralta V (2013) Spontaneous parkinsonism with cognitive impairment in antipsychotic-native patients with first-episode psychosis: a 6-month follow-up study. Schizophr Bull [Epub ahead of print]
Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S (2002) Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 162:42–49
Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience 198:221–231
Poletti M, De Rosa A, Bonucelli U (2012) Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci 317:97–102
Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776–786
Van Snellenberg JX, Torres IJ, Thornton AE (2006) Functional neuroimaging of working memory in schizophrenia: task performance as a moderating variable. Neuropsychology 20:497–510
Kim E, Howes OD, Turkheimer FE, Kim BH, Jeong JM, Kim JW, Lee JS, Jang IJ, Shin SG, Kapur S, Kwon JS (2013) The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: a dual [11C]raclopride and [18F]FDG imaging study with aripiprazole. Psychopharmacology 227:221–229
Bubser M, Byun N, Wood MR, Jones CK (2012) Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol 208:121–166
Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R (2006) Clozapine and risperidone enhancement (CARE) study group. N Engl J Med 354:472–482
Ojeda N, Pena J, Schretlen DJ, Sanchez P, Aretouli E, Elizagarate E, Ezcurra J, Gutierrez M (2012) Hierarchical structure of the cognitive processes in schizophrenia; the fundamental role of processing speed. Schizophr Res 135:72–78
Barch DM, Moore H, Nee DE, Manoach DS, Luck SJ (2012) CNTRICS imaging biomarkers selection: working memory. Schizophr Bull 38:43–52
Fusar-Poli P, Deste G, Smieskova R, Barlatti S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69:562–571
Bowie CR, Harvey PD (2005) Cognition in schizophrenia: impairments, determinants and functional importance. Psychiatr Clin N Am 28:613–633
Patel MX, Arista IA, Taylor M, Barnes TR (2013) How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res 149(1–3):141–148
Zhornistky S, Stip E, Pampoulova T, Rizkallah E, Lipp O, Bentaleb LA, Chiasson JP, Potvin S (2010) Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord 25:2188–2194
Toupoulouand T, Murray RM (2004) Verbal memory deficits in patients with schizophrenia: an important future target for treatment. Expert Rev Neurother 4:43–52
Kim JH, Byun HJ (2007) Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther 32:461–467
Acknowledgments
This study was funded by the Canadian Occupational Therapy Foundation and by the Fonds de la Recherche du Québec en Santé (FRQ-S). ES is holder of the Eli Lilly Chair of schizophrenia from the University of Montreal.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Potvin, S., Aubin, G. & Stip, E. Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. Eur Arch Psychiatry Clin Neurosci 265, 147–154 (2015). https://doi.org/10.1007/s00406-014-0511-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-014-0511-y